Syndax Pharmaceuticals Inc
No SEC Form 4 filings for $SNDX in the last 30 days.
See all $SNDX insider activity →Syndax Pharmaceuticals (NASDAQ:SNDX) reported Q2 revenue of about $115 million, nearly doubling year over year, with Revuforj at $55 million (+91% YoY) and Niktimvo at $60 million (+67% YoY). Despite the growth, shares fell 2.41%. Management cited patient-start variability and ongoing profitability constraints, while pending Q4 data and pipeline updates remain key.
Syndax (SNDX) discussed its Q2 2026 earnings call, focusing on menin inhibitor Revuforj and axatilimab-related pipeline. Revuforj net revenue was $55 million, up 12% QoQ, with about 1,500 prescriptions, up 15% QoQ. Niktimvo Q2 net revenue rose to $60 million, up 67% YoY. The company reiterated expectations for Revuforj peak US net revenue above $2 billion.
Syndax Pharmaceuticals Inc (SNDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sndx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update • Total revenue of $73 million in 2Q26, a 92% year-over-year increase – • Revuforj ® (revumenib) net revenue of $54.7 million in 2Q26, a 91% ye
Over the past 7 days, alphai's AI scored 2 news stories mentioning SNDX (Syndax Pharmaceuticals Inc). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent SNDX coverage spans market movers, earnings and technology.
Near-doubled revenue did not translate into immediate confidence due to patient-start variability, distant profitability, and partner accounting that understates Niktimvo economics.
The call emphasizes accelerating commercial momentum for Revuforj and continued demand for Niktimvo, with additional upcoming clinical data catalysts for Revumenib and axatilimab.
Commercial momentum is strengthening (large YoY revenue growth and prescription growth), while near-term catalysts are tied to 4Q26 Phase 2 topline data for axatilimab.
The article expands Syndax’s clinical roadmap across myelofibrosis, IPF, and EGFR-mutant lung cancer, creating multiple upcoming decision points (trial starts and IND timing).
This is a routine insider sale disclosure, not a new operating or regulatory catalyst.
alphai scores every news story that mentions SNDX with an AI model for sentiment and relevance, and aggregates insider trades from Syndax Pharmaceuticals Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Syndax Pharmaceuticals (NASDAQ:SNDX) reported Q2 revenue of about $115 million, nearly doubling year over year, with Revuforj at $55 million (+91% YoY) and Niktimvo at $60 million (+67% YoY). Despite the growth, shares fell 2.41%. Management cited patient-start variability and ongoing profitability constraints, while pending Q4 data and pipeline updates remain key.
7 min readSyndax (SNDX) discussed its Q2 2026 earnings call, focusing on menin inhibitor Revuforj and axatilimab-related pipeline. Revuforj net revenue was $55 million, up 12% QoQ, with about 1,500 prescriptions, up 15% QoQ. Niktimvo Q2 net revenue rose to $60 million, up 67% YoY. The company reiterated expectations for Revuforj peak US net revenue above $2 billion.
7 min readSyndax Pharmaceuticals Inc (SNDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sndx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update • Total revenue of $73 million in 2Q26, a 92% year-over-year increase – • Revuforj ® (revumenib) net revenue of $54.7 million in 2Q26, a 91% ye
6 min readSyndax Pharmaceuticals (SNDX) outlined plans to expand Revuforj (menin inhibition) into myelofibrosis, including a Q4 proof-of-principle phase 1/2 trial in about 30 patients. It also expects to file an IND for SNDX-62122 in 2027. Syndax and Incyte are advancing axatilimab (Niktimvo) in chronic GVHD and IPF, and introduced SNDX-4321 for EGFR-mutant NSCLC with an IND expected by year-end.
7 min readMetzger Michael A (Chief Executive Officer) sold 32,375 shares of Syndax Pharmaceuticals Inc (SNDX) at $24.24 ($0.78M total) on 2026-07-08 under a Rule 10b5-1 trading plan.
1 min readBotwood Nicholas A.J. (Head of R&D, CMO) sold 65,515 shares of Syndax Pharmaceuticals Inc (SNDX) at an average of $18.07 ($18.00–$18.14, $1.18M total) across 2 trades over 2026-06-11 to 2026-06-12 under a Rule 10b5-1 trading plan.
2 min readSyndax Pharmaceuticals reported multiple Revuforj (revumenib) abstracts at EHA 2026. In ROAR (R/R NPM1m/KMT2Ar), interim ORR was 82% (9/11) with 64% (7/11) CR/CRh. In SNDX-5613-0708 (newly diagnosed NPM1m/KMT2Ar), CRc was 97% (34/35) and MRD negativity 86% (25/29). Post-HSCT AUGMENT-101 analysis showed 12-month OS 95%. In SAVE (R/R AML), ORR was 88% (37/42) and MRD negativity 68% (25/37).
6 min readSyndax Pharmaceuticals Inc (SNDX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 d105044dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 Execution Version SYNDAX PHARMACEUTICALS, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of June 10, 2026 2.25% Convertible Senior Notes due 2031 TABLE OF CONTENTS P AGE ARTICLE 1 DEFINITIO
6 min readSyndax Pharmaceuticals Inc (SNDX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 sndx-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 SYNDAX PHARMACEUTICALS, Inc. 2026 Equity Incentive Plan Adopted by the Board of Directors: April 30 , 2026 Approved by the Stockholders: June 10 , 2026 1. General. (a) Successor to and Continuation of Prior Plan . The Plan is
4 min readSyndax Pharmaceuticals (NASDAQ: SNDX) said it entered private subscription agreements to issue $250.0 million of 2.25% Convertible Senior Notes due 2031, with an expected June 10, 2026 closing. Net proceeds are estimated at about $243 million for general corporate purposes. Notes pay semiannual interest, mature June 15, 2031, and have an initial conversion price of ~$24.76/share.
4 min read
